The nootropic market is worth over $5 billion globally and growing fast. Walk into any supplement retailer or scroll through your social feed long enough and you'll find confident claims about sharper focus, better memory, and protected brain tissue. Some of these products cost $80 to $150 per month. Very few of them have the science to back the price tag.
That's not cynicism. It's what the evidence actually shows when you sort it tier by tier. And a 2026 trial published in JAMA on urolithin A gives us a useful place to start, because it illustrates perfectly how "promising research" and "proven benefit" are not the same thing.
Tier One: What Actually Has Signal
Before dismissing the entire category, it's worth being precise. A small number of compounds do have meaningful, replicated human evidence for cognitive outcomes. The list is shorter than the supplement industry wants you to believe.
Creatine monohydrate is probably the most evidence-backed supplement for cognitive performance, which surprises people who think of it only as a gym staple. Multiple randomized controlled trials show that creatine supplementation meaningfully improves working memory and processing speed. The catch: those effects are most robust under conditions of cognitive stress, specifically sleep deprivation, intense mental fatigue, or caloric restriction.
In well-rested adults eating a balanced diet, the cognitive gains from creatine are real but modest. A 2024 meta-analysis found effect sizes in the small-to-moderate range for memory tasks under stress, dropping to negligible in baseline-rested participants. If you're regularly short on sleep, there may be a genuine case for creatine supplementation. It's also cheap, safe at standard doses (3 to 5 grams per day), and has an enormous safety record from decades of athletic research. For a broader look at what the evidence actually supports in 2026, Sports Supplements in 2026: What the Science Says Now is worth your time.
Omega-3 fatty acids (specifically DHA) have solid mechanistic backing and decent epidemiological data linking higher intake to slower cognitive decline. Clinical trial results on function in healthy adults are mixed, though populations with low baseline intake show more consistent benefit. It's not a cognitive enhancer in the traditional sense, but the risk-to-benefit profile is favorable enough that it belongs in the legitimate tier.
Caffeine, combined with L-theanine, has consistent short-term evidence for attention, reaction time, and working memory. The doses matter: roughly 100 to 200mg caffeine with 100 to 200mg L-theanine. This combination shows up repeatedly in well-designed human trials. It's not glamorous, but it works.
Tier Two: Mechanism Without Function
This is where urolithin A currently sits, and it's an instructive category.
Urolithin A is a compound produced in the gut from polyphenols found in pomegranates and certain berries. It's attracted serious scientific interest because of its effects on mitophagy, the cellular process by which damaged mitochondria are cleared and replaced. In animal models, it improves brain energy metabolism. In human trials, it's shown genuine benefits for muscle function and mitochondrial health in older adults.
The 2026 JAMA trial was the first well-powered randomized controlled trial to look specifically at cognitive outcomes. The findings were interesting and deflating in equal measure: participants taking urolithin A showed measurable improvements in cerebral blood flow. The brain's vascular response was real. And yet, on every validated cognitive performance measure, including memory, executive function, and processing speed, there was no statistically significant difference from placebo.
Better blood flow to the brain without better brain performance is a mechanistic win attached to a functional null result. That's not nothing. It may mean the trial was too short (12 weeks), or that the dose needs refinement, or that blood flow alone isn't the limiting factor in this population. Future trials may tell a different story. But right now, in 2026, paying a premium for urolithin A because of its cognitive claims is getting ahead of the evidence.
Other compounds in this tier include lion's mane mushroom, which shows genuine neurotrophin-related activity in cell culture and some animal work, but whose human trial data is limited to small studies with inconsistent methodology. Phosphatidylserine has a similar profile: solid mechanism, early human trial promise, insufficient large-scale replication. Bacopa monnieri has the most human trial data of the adaptogen-adjacent compounds, with some positive signals on memory consolidation over 8 to 12 weeks, but effect sizes are small and study quality is variable.
None of this means these compounds are useless. It means the evidence isn't there yet to recommend spending significant money on them, particularly at the doses most supplements actually contain.
Tier Three: Marketing Dressed as Science
This is the largest tier, by sales volume and by number of products.
The majority of nootropic blends sold in 2026 share a common structure: a long ingredient list featuring recognizable names (lion's mane, bacopa, ginkgo, phosphatidylserine, acetyl-L-carnitine), proprietary blend labeling that obscures individual doses, and a price point between $60 and $120 per month.
The problem isn't always the ingredients. The problem is the doses. When researchers have demonstrated any effect from lion's mane, it's typically at 500mg to 3,000mg per day in human trials. Many commercial products contain 50 to 150mg, buried in a blend. That's not a therapeutic dose. That's a label claim.
Ginkgo biloba is a useful case study here. It was one of the most heavily marketed cognitive supplements of the 2000s. A large, well-funded randomized controlled trial, the Ginkgo Evaluation of Memory study, followed over 3,000 adults for several years and found no significant reduction in cognitive decline or dementia incidence compared to placebo. The marketing outlasted the science by about a decade. You'll still find it in blends today.
If you're trying to audit your own supplement spending, Your Supplement Stack: What You Can Actually Stop Buying applies much of the same evidence-tier thinking to supplements broadly. The pattern is consistent: the more a product leans on proprietary blends, the less you should trust the efficacy claims.
The Lifestyle Factors That Outperform Most Supplements
This isn't a pivot to avoid the question. It's a data point that keeps showing up and deserves to be stated plainly: the effect sizes for lifestyle interventions on cognitive performance and long-term brain health are, in most head-to-head comparisons, larger than those from any supplement currently available.
Sleep is the clearest example. Cognitive performance degrades measurably with even modest sleep restriction. The irony of taking a $100 nootropic stack while sleeping six hours a night is not subtle. If sleep consistency is an issue for you, understanding how circadian disruption affects mental function is a better starting point than any supplement. The research on how an erratic sleep schedule can hurt your mental health makes that case clearly.
Exercise has some of the strongest longitudinal data for brain health of any intervention, pharmacological or otherwise. Aerobic training in particular drives BDNF expression, improves hippocampal volume, and reduces risk of cognitive decline. And the dose required is lower than most people assume. Research consistently shows that even short, structured training sessions deliver meaningful physiological benefits. If you haven't read the evidence on how you don't need hours in the gym to buy years of life, the data there is worth your attention.
Protein adequacy also matters for brain health in ways that are under-discussed. Neurotransmitter synthesis depends on amino acid availability. Choline, found in eggs and meat, is a precursor to acetylcholine. Adequate protein intake, particularly after 50, is associated with better cognitive outcomes in aging populations. Protein for Muscle After 50: What Actually Works covers the intake evidence, most of which applies directly to brain health as well.
How to Think About Brain Health Spending
Here's a practical framework for evaluating any cognitive supplement claim.
- Ask what tier the evidence is in. Is there a randomized controlled trial in humans showing a functional cognitive outcome? If the answer is no, you're in the mechanism or marketing tier.
- Check the dose against published research. If a product uses a proprietary blend, you can't verify this. That's usually intentional.
- Look at the control conditions. A supplement that improves cognition in sleep-deprived subjects tells you something very different from one that works in well-rested people eating a good diet.
- Consider the opportunity cost. $100 per month spent on an unproven nootropic blend is $1,200 per year. That money applied to better food, a gym membership, or improved sleep infrastructure would almost certainly produce larger measurable effects.
- Be skeptical of urgency and stacking language. "Synergistic formula" and "clinically studied ingredients" are legally distinct from "clinically proven product." Ingredient studies don't validate blends.
The science of brain health is genuinely exciting right now. Urolithin A may yet earn a spot in a higher tier. Lion's mane may accumulate the trial data it currently lacks. But promising mechanisms are not the same as proven outcomes, and the supplement industry has a long history of monetizing the gap between the two.
Creatine if you're sleep-deprived. Omega-3s if your intake is low. Caffeine and L-theanine if you want something that works today. Good sleep, consistent exercise, and adequate protein for everything else. That's not a supplement stack. That's what the evidence actually says.